Morgan Stanley says REDEFINE-2 misses opportunity to differentiate in diabetes
Morgan Stanley notes Novo Nordisk (NVO) disclosed headline data for CagriSema in REDEFINE-2, with a weight loss and safety ...
Viking Therapeutics: Signs Of Insufficient Differentiation In Obesity Treatment (Rating Downgrade)
Viking Therapeutics' plans to launch VK2735 with an auto-injector could delay regulatory approval. Click here to read why ...
Novo Nordisk under pressure as obesity drug disappoints in diabetes trial
Shares of Novo Nordisk (NVO) are sliding in Monday trading after the company announces results for its trial of weight-loss drug CagriSema.
Novo’s Wegovy successor disappoints in second large trial
A study in people with obesity and diabetes again found CagriSema helps people lose weight, but not by enough to clearly ...
EL PAÍS English4d
New anti-obesity drugs already outperform Ozempic
It was the first in a series of drugs that are, for the first time, effective against obesity and can help lessen the moral ...
BioSpace8d
Obesity Late-Comer AbbVie Inks Up to $2.2B Amylin Deal With Gubra
AbbVie on Monday jumped into the hot weight-loss space, looking to gain ground on its Big Pharma peers, with a licensing deal ...
Investing14d
Novo shares rise as HIMS halt sales of some obesity drugs
Analysts see CagriSema and oral semaglutide as underappreciated catalysts and believe the company’s guidance remains conservative. "We simply believe in Novo’s guide as historically having been ...
Morningstar14d
ADOCIA Reports Fourth Quarter 2024 Financial Results and Provides a Business Update
“The fourth quarter of 2024 was marked by two key announcements: the filing of patents covering, in particular, BioChaperone CagriSema—a stable combination of cagrilintide and semaglutide ...